Glioblastoma Multiforme Clinical Trial
Official title:
A Phase II Study in Relapsing Glioblastoma of Intraarterial Concurrent Chemoradiation Therapy Using IA Carboplatin
Treatment of glioblastoma involves an optimal surgery, followed by a combination of radiation
and temozolomide chemotherapy. Progression-free survival (PFS) with this treatment is only
6.9 months and relapse is the norm. The rationale behind the fact that limited chemotherapy
agents are available in the treatment of malignant gliomas is related to the blood-brain
barrier (BBB), which limits drug entry to the brain. Intraarterial (IA) chemotherapy allows
to circumvent this. Using IA delivery of carboplatin, the investigators have observed
responses in 70% of patients for a median PFS of 5 months. Median survival from study entry
was 11 months, whereas the overall survival 23 months. How can we improve on this? By
coupling radiation with a chemotherapeutic which is also a potent radiosensitizer such as
carboplatin.
Study design: In this phase I/II trial, patients will be treated at recurrence; a surgery
will be performed for cytoreduction and to obtain tumor sample, followed with a combination
of re-irradiation and IA carboplatin chemotherapy. A careful escalation scheme from
1.5Gy/fraction up to 3.5Gy/fraction will allow the investigators to determine the optimal
re-irradiation dose (10 fractions of radiation over 2 weeks). Toxicity will be assessed
according to the NCIC common toxicity criteria. Combined with radiation, patients will
receive 2 treatments of IA carboplatin, 400 mg/m2, 4 hours prior to the first and the sixth
radiation fraction. IA treatments will then be continued on a monthly basis, up to a total of
12 months, or until progression.
Outcome measurements: Tumor response will be evaluated using the RANO criteria by magnetic
resonance imaging monthly. The investigators will also acquire a sequence that enables the
measurement of cerebral blood flow, cerebral blood volume and blood vessel permeability that
are all relevant to understand the delivery of therapeutics to the CNS. Primary outcome will
be OS and PFS. Secondary outcome will be QOL, neurocognition, and carboplatin delivery.
In vitro intracellular carboplatin accumulation: Tumor samples from re-operation will be be
analyzed for intracellular Pt concentration by ICP-MS. The amount of Pt bound to DNA will be
measured. The level of apoptosis will be determined for each of the sample.
Putting together these data will allow to correlate clinical and radiological response to
QOL, NC (MOCA), and to delivery surrogates for the IA infusion and intracellular penetration
of carboplatin.
A phase II study in relapsing glioblastomas (GBM) using concurrent intraarterial carboplatin
chemoradiation therapy.
BACKGROUND - Contemporary treatment of GBM brain tumors involves a first-line treatment in
which the patient receives a surgical procedure followed by a combination of radiation and
temozolomide-based chemotherapy1. Unfortunately, this regimen improves patient survival only
modestly, with a progression-free survival (PFS) of 6 months, and an overall survival of 14
months. Glioblastoma remains an incurable disease characterized by relapse and disease
progression. There is no established second-line treatment for relapsing GBM, and the most
used (BCNU chemotherapy) results in a PFS of only 2 months. As the investigators have shown,
treatment can be considerably improved by circumventing the limitation of chemotherapeutic
agents(CA) to cross the blood-brain barrier (BBB) and enter the central nervous system (CNS).
The investigators have focused its research on 3 essential aspects of GBM treatment: 1)
alternate delivery approaches to bypass the BBB; 2) magnetic resonance imaging (MRI) to
characterize tumor blood supply and predict therapeutics delivery to the tumor; 3)
synergestic interplay of radiation and platinum drugs to improve brain tumor therapy. This is
the first study to ever attempt bridging these 3 aspects within the same project.
Alternate delivery approaches to bypass the BBB.
Although different approaches have been tested in the researcher's lab to bypass the BBB, the
most applicable to the clinic is the intraarterial infusion of chemotherapy (IA). It allows
to circumvent the BBB via the first pass effect, resulting in a local plasma peak
concentration increase of the CA by up to a 5-fold factor, maximizing CNS drug exposure. It
also decreases systemic distribution of the CA thereby reducing toxicities and side effects.
Over the last 15 years, the principal investigator has treated more than 720 patients using
this IA approach, 422 of which had glioblastoma. This is the largest of such series. Based on
this extensive experience, the investigators have convincingly shown that the procedure is
safe and well tolerated. Using IA carboplatin in GBM relapse, a response in 70% of patients,
and a 22 months overall survival + an increase in PFS to 5 months has been observed. This
represents an impressive survival increase of 9 months. Time is ripe to improve these results
in hope to cure this hard-to-treat cancer someday; hence the 2 additional measures discussed
next.
MRI characterization. MRI is routinely used to monitor GBM response to treatment. It could
also help us guide treatment and predict responses. Indeed, the investigators have recently
developed a novel MRI sequence that enables the simultaneous measurement of cerebral blood
flow (CBF), cerebral blood volume (CBV) and vessel permeability; these surrogates are all
relevant to predict delivery of therapeutics to CNS tumors. This sequence has been tested and
has met strict quality criteria. This will help decide the artery into which IA chemotherapy
is delivered, and predict CA delivery and possibly tumor response.
Synergistic interplay of radiation and platinum drugs. Radiotherapy is the most effective
single-treatment modality for GBM tumors, but it controls the disease only transiently. A way
to improve treatment consists of coupling radiation with a potent radiosensitizer.
Carboplatin (Ca), a platinum (Pt) drug, is ideally suited for this7. Our group has
demonstrated that the addition of Ca to ionizing radiation produced significantly more DNA
strand breaks. In numerous cell lines, combining radiotherapy and Ca was found to increase
cell death. In a mouse model, the investigators observed a maximum antitumor effect with
Pt-Ca administration at 4 h or 48 h prior to irradiation. This timing correlated to the
highest levels of Pt bound to DNA. Concurrent Pt-Ca and radiation treatment represents a
common modality for treating a variety of cancers. Unfortunately, since this class of drug
does not readily cross the BBB when administered via the standard iv routes, they are not
used to treat GBM.
After years of interdisciplinary collaboration, the investigators demonstrated the following
key factors in our pre-clinical F98-Fischer GBM model: 1- the use of the IA route increased
Ca accumulation into the nucleus of tumor cells by a whooping 20-fold factor compared to the
iv route. 2- While testing for 5 different Platinum compounds administered to the CNS by
different routes, radiotherapy, IA carboplatin + radiotherapy was by far the best therapeutic
modality in terms OS.
AIM - To conduct a phase I/II clinical study in which: (1) patients with relapsing GBM will
be treated with a novel IA chemoradiation with Ca. (2) the new MRI sequence will be used to
maximize the intraarterial catheter position in relation to individual tumor vasculature.
Moreover, the investigators will assess whether the sequence can serve as a predictor of Ca
delivery to the CNS, tumor response and patients survival. (3) Using tumor sample of each
patient, to proceed to in vitro analysis of efflux pumps expression levels, DNA-bound Ca
levels, and in vitro radiation linked to cell death study to predict in vivo tumor response.
With this structuring and translational project, the investigators ultimate goal is to
personalize GBM treatment for each patient based on the MRI and in vitro biological data.
HYPOTHESES - (1) IA Ca will show strong synergy with radiation and will act as a potent
radiosensitizer. (2) MRI data analysis on blood flow, volume and vessel permeability will
predict the extent of delivery of Ca to the tumor and the level of hypoxia affecting
radiation effectiveness. Hence, this should allow to predict response to treatment. It will
also help maximize the catheter position in the cerebral vascular tree. (3) In vitro
intracellular penetration of carboplatin and radiation testing, as well as expression of
efflux pumps will predict treatment effectiveness and time-correlate Ca binding to DNA with
cell entrance flux. Putting together these data will allow correlating clinical and
radiological response to quality of life (QOL), and to delivery surrogates for the IA
infusion and intracellular penetration of carboplatin.
STUDY DESIGN: IA carboplatin and radiation - Patients with GBM progressing after the first
line of treatment will be eligible. In this phase I/II trial, all patients will be treated at
recurrence; a surgery will be performed for cytoreduction during which tumor samples will be
collected, followed by a combination of radiation and IA Ca. A dose escalation protocol with
consideration of the cumulative biologically effective dose and the normalized total dose
will be used to determine the optimal re-irradiation dose in terms of acceptable toxicity and
efficacy. We will use 10 fractions of radiation over 2 weeks. This will allow to benefit from
the protective effects of fractionation (normal tissue repair), while being tolerable in the
preservation of QOL. Escalation scheme from 1.5Gy/fraction up to 3.5Gy/fraction will allow us
to control for neurotoxicity. A 12 weeks observational period has been planned between each
escalation to detect any undesired toxicity. Toxicity will be graded according to the
National Cancer Institute (NCI) common toxicity criteria and grade III or IV will be
considered significant. Pending the occurrence of such toxicity, the patient will be
withdrawn from the study. Moreover, 3 instances of a grade III or IV toxicity will halt the
escalation scheme. The prior radiation dose level will then be considered as the established
safe level, and 10 more patients will be accrued at this level.
Combined with radiation, patients will receive 2 treatments of IA carboplatin12 (400 mg/m2),
4 hours prior to the first and the sixth radiation fraction (of a total of 10). IA treatments
will then be continued on a monthly basis as a single treatment modality for consolidation,
up to a total of 12 months, or until progression.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |